192 related articles for article (PubMed ID: 25091619)
1. A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study.
Duska LR; Blessing JA; Rotmensch J; Mannel RS; Hanjani P; Rose PG; Dizon DS
Gynecol Oncol; 2014 Oct; 135(1):44-8. PubMed ID: 25091619
[TBL] [Abstract][Full Text] [Related]
2. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Hensley ML; Blessing JA; Degeest K; Abulafia O; Rose PG; Homesley HD
Gynecol Oncol; 2008 Jun; 109(3):323-8. PubMed ID: 18394689
[TBL] [Abstract][Full Text] [Related]
3. A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study.
McCourt CK; Deng W; Dizon DS; Lankes HA; Birrer MJ; Lomme MM; Powell MA; Kendrick JE; Saltzman JN; Warshal D; Tenney ME; Kushner DM; Aghajanian C
Gynecol Oncol; 2017 Jan; 144(1):101-106. PubMed ID: 28029447
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.
De Geest K; Blessing JA; Morris RT; Yamada SD; Monk BJ; Zweizig SL; Matei D; Muller CY; Richards WE
J Clin Oncol; 2010 Jan; 28(1):149-53. PubMed ID: 19917861
[TBL] [Abstract][Full Text] [Related]
5. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.
Hensley ML; Blessing JA; Mannel R; Rose PG
Gynecol Oncol; 2008 Jun; 109(3):329-34. PubMed ID: 18534250
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Hensley ML; Sill MW; Scribner DR; Brown J; Debernardo RL; Hartenbach EM; McCourt CK; Bosscher JR; Gehrig PA
Gynecol Oncol; 2009 Dec; 115(3):460-5. PubMed ID: 19811811
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.
Hyman DM; Sill MW; Lankes HA; Piekarz R; Shahin MS; Ridgway MR; Backes F; Tenney ME; Mathews CA; Hoffman JS; Aghajanian C; Hensley ML
Gynecol Oncol; 2017 Jan; 144(1):96-100. PubMed ID: 28094040
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P.
Dizon DS; Blessing JA; McMeekin DS; Sharma SK; Disilvestro P; Alvarez RD
J Clin Oncol; 2009 Jul; 27(19):3104-8. PubMed ID: 19451430
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.
Ott PA; Hamilton A; Jones A; Haas N; Shore T; Liddell S; Christos PJ; Doyle LA; Millward M; Muggia FM; Pavlick AC
PLoS One; 2010 Jan; 5(1):e8714. PubMed ID: 20098694
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study.
Gallup DG; Blessing JA; Andersen W; Morgan MA;
Gynecol Oncol; 2003 Apr; 89(1):48-51. PubMed ID: 12694653
[TBL] [Abstract][Full Text] [Related]
11. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Sutton G; Blessing J; Hanjani P; Kramer P;
Gynecol Oncol; 2005 Mar; 96(3):749-52. PubMed ID: 15721421
[TBL] [Abstract][Full Text] [Related]
12. Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma.
Burotto M; Edgerly M; Poruchynsky M; Velarde M; Wilkerson J; Kotz H; Bates S; Balasubramaniam S; Fojo T
Oncologist; 2015 Jul; 20(7):725-6. PubMed ID: 26040622
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.
Burtness BA; Manola J; Axelrod R; Argiris A; Forastiere AA;
Ann Oncol; 2008 May; 19(5):977-83. PubMed ID: 18296423
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study.
Look KY; Sandler A; Blessing JA; Lucci JA; Rose PG;
Gynecol Oncol; 2004 Feb; 92(2):644-7. PubMed ID: 14766260
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer.
Denduluri N; Lee JJ; Walshe J; Berman AW; Vatas U; Chow CK; Steinberg SM; Cox MC; Low JA; Swain SM
Invest New Drugs; 2007 Feb; 25(1):63-7. PubMed ID: 16933153
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group.
Liu G; Chen YH; Dipaola R; Carducci M; Wilding G
Clin Genitourin Cancer; 2012 Jun; 10(2):99-105. PubMed ID: 22386239
[TBL] [Abstract][Full Text] [Related]
17. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.
Monk BJ; Blessing JA; Street DG; Muller CY; Burke JJ; Hensley ML
Gynecol Oncol; 2012 Jan; 124(1):48-52. PubMed ID: 21996263
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma.
Posadas EM; Undevia S; Manchen E; Wade JL; Colevas AD; Karrison T; Vokes EE; Stadler WM
Cancer Biol Ther; 2007 Apr; 6(4):490-3. PubMed ID: 17457044
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
Hensley ML; Wathen JK; Maki RG; Araujo DM; Sutton G; Priebat DA; George S; Soslow RA; Baker LH
Cancer; 2013 Apr; 119(8):1555-61. PubMed ID: 23335221
[TBL] [Abstract][Full Text] [Related]
20. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.
Rose PG; Blessing JA; Soper JT; Barter JF
Gynecol Oncol; 1998 Aug; 70(2):267-71. PubMed ID: 9740703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
